What is BrainsWay?
BrainsWay operates at the intersection of advanced engineering and clinical psychiatry, specializing in noninvasive neurostimulation solutions. The company is best known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which provides a non-pharmacological alternative for patients suffering from depression, obsessive-compulsive disorder, and smoking addiction. By delivering targeted electromagnetic pulses to specific brain regions, the platform offers a sophisticated therapeutic modality for healthcare providers and hospitals. As a global medical technology entity, BrainsWay maintains a rigorous focus on evidence-based innovation, ensuring that its medical devices meet the highest standards of clinical efficacy and patient safety in the evolving landscape of mental health care.
How much funding has BrainsWay raised?
BrainsWay has raised a total of $20M across 1 funding round:
Stock/Share Issuance
$20M
Stock/Share Issuance (2025): $20M, investors not publicly disclosed
Key Investors in BrainsWay
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for BrainsWay?
With the recent capital deployment, BrainsWay is poised to enter a new phase of enterprise-level growth. The strategic roadmap likely involves scaling the commercial distribution of its Deep TMS systems to meet the rising global demand for mental health interventions. Furthermore, the company is expected to prioritize research and development initiatives aimed at broadening the clinical applications of its neurostimulation technology. By strengthening its market presence and enhancing its technological infrastructure, BrainsWay aims to solidify its role as a cornerstone of modern psychiatric care, ultimately improving patient outcomes through continued medical device innovation and strategic market expansion.
See full BrainsWay company page
